Loading stock data…
$1.29-0.06 (-4.44%)
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States.
PMV Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.29 with a market capitalization of $113M. Wall Street consensus targets $4.20 (5 analysts), implying a +225.6% move over the next 12 months. The stock is currently 32% below its 52-week high of $1.91, remaining 0.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$18.88M↑ | -$19.02M↑ | -$19.24M↑ | -$22.52M↑ | -$22.88M |
| Net Income | -$18.09M↓ | -$18.04M | -$18.04M↑ | -$21.06M↑ | -$21.21M |
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural c...